Press Releases [2006]
ALMAC DIAGNOSTICS MULTI YEAR LICENSE AGREEMENT WITH GENEGO CRAIGAVON, Northern Ireland and St. Joseph, Michigan, December 19th, 2006 – Almac Diagnostics, a division of Almac Group, and GeneGo, Inc., a leading provider of software, databases and services for systems biology, announced today that Almac Diagnostics has licensed their flagship data mining suite, MetaCore™. The multiple-year agreement will allow Almac Diagnostics’ scientists in the UK and US to use MetaCore™ in the development of novel microarray-based products for the diagnosis and treatment of cancer. Almac Diagnostics’ Genomic Services division that delivers comprehensive genomic services to academic, biotech and pharmaceutical customers will also use MetaCore™. Almac values the completeness and quality of content coverage in MetaCore™ from signaling ligands to core metabolic pathways, its intuitive interface and comprehensive automated analysis workflows. “We compared several platforms before we finally decided on GeneGo. MetaCore™ has broad and deep, high quality content coverage, which was important to us. Furthermore its ability to work with mixed IDs is critical for our internal R&D work and service offerings based on our unique DSA™ (patent pending) research tools,” said Dr. Vitali Proutski, Bioinformatics Manager at Almac Diagnostics. “We were also very impressed by GeneGo’s responsiveness and strong customer support which we feel is vital in relationships with our partners.” “We are very pleased to welcome Almac Diagnostics as a new GeneGo customer. Our experience with them during the thorough evaluation was very positive, with constant communication between Almac Diagnostics and GeneGo scientists,” said Julie Bryant, Vice President of Business Development at GeneGo. “Our products are gaining momentum in clinical diagnostics, both on the development side and among practitioners. Almac combines both as a highly reputable, scientific oriented new generation CRO.” About Almac Diagnostics Almac Diagnostics develops, markets and supplies, leading edge genomic products and services. It is a member of the Almac Group, an organization providing services from R&D through clinical development to manufacture of pharmaceutical product. Almac Diagnostics has two divisions:
CHANG GUNG UNIVERSITY UPGRADES AND EXTENDS THEIR AGREEMENT WITH GENEGO TO ACCESS METACORE™ AND MAPEDITOR™ St. Joseph, Michigan, December 12th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that Chang Gung University (CGU), Taiwan has upgraded their MetaCore™ web portal license to a permanent in house server installation. CGU has also licensed MapEditor™, a new customization product for drawing and editing pathways maps using MetaCore's high quality, manually curated back end content database. An extensive group of CGU researchers will be using MetaCore™ and MapEditor™ for analysis of gene expression, proteomic and metabolomic data in a broad range of life science fields. They also plan to produce their own pathway maps using MapEditor™ that will be accessible to the Chang Gung University research community. The agreement was made possible through GeneGo's Taiwanese distributor Tri-I Biotech. "GeneGo's MetaCore™ and MapEditor™ is one of the integrated bioinformatics platforms installed in the Chang Gung Bioinformatics Center for analysis of data generated from research projects of different disciplines. Current and ongoing projects include the identification of biomarkers that can reveal the presence of nasopharyngeal carcinoma (NPC) in a blood test; the Trichomonas vaginalis Systems Biology Project and the Acanthamoeba Expressed Sequence Tag Project. These powerful tools will highly improve our research stretch" said Professor Tang. "We are pleased that Dr. Tang has extended his MetaCore™ license and added our latest product, MapEditor™" said JulieBryant, Vice President of Business Development at GeneGo. "Taiwan is an important, fast growing market for us, as its research is well known in different areas of life sciences."
GENEGO LAUNCHES TWO NOVEL PATHWAY EDITING PRODUCTS, MAPEDITOR™ AND METALINK™ St. Joseph, Michigan, October 24th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the launch of two new products, MapEditor™ and MetaLink™. The products are add-on modules in the MetaCore™ environment designed for integration, editing and mapping custom interactions data. MapEditor™ enables the generation of custom pathway maps starting from scratch, converting a network in to a pathway map or editing one of the existing 500 proprietary maps from MetaCore™. This allows GeneGo customers to develop NEW pathway maps based on their proprietary data that is only accessible to their company. GeneGo’s maps are becoming the industry standard and are currently widely available via the iPath™ Online BioAtlas from Invitrogen at www.invitrogen.com/ipath. MetaLink™ allows users to batch upload their own protein association data produced by yeast-twohybrid screens, gene co-expression, pull-down assays, text mining and other methods in MetaCore™ and build networks on the fly overlaying their interactions in the context of manually curated interactions. The accompanying gene expression and other molecular omics data can be mapped and prioritized on the resulting customized networks. “MapEditor™ and MetaLink™ were developed in conjunction with our pharmaceutical customers, who needed customization tools to deal with their proprietary experimental interactions data not yet reported in the literature,” said Julie Bryant, Vice President of Business Development at GeneGo. “The new products round up our customization suite of tools which also includes PathwayEditor, launched two years ago. With these additions, the MetaCore™ platform has become a truly universal environment for functional data mining, capable of handling analysis of any type of molecular omics data and gene/protein association data. The main functional blocks in MetaCore™, canonical maps and networks are now completely editable, seamlessly integrated and internally consistent.”
DOW NEUROBIOLOGY LABROATORIES EXTENDS THEIR METACORE™ LICENSES FROM GENEGO St. Joseph, Michigan, October 17th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Robert S. Dow Neurobiology Laboratories extended their MetaCore™ license. Scientists in RSDNL have been using MetaCore™ for analysis of proteomics and gene expression data for understanding ischemic brain injury and its prevention. MetaCore™ is an expert yet easy to use platform for functional data mining. With intuitive, one-click workflows, it provides bench biologists with a comprehensive overview of pathways, networks, functional modules and processes perturbed in disease and under drug treatment. “During the past year, we have used MetaCore™ in analyzing our quantitative proteomic data on ischemic rodent brains,” said Dr. An Zhou, a scientist at the RSDNL. “MetaCore™ allows us to efficiently handle multiple sets of high throughput proteomic data with statistics and visual presentation, as well as to identify pathways and networks that are unique to different ischemic conditions of the brain”. “Research at the Robert S. Dow Neurobiology Labs,” said Dr. Roger Simon, the director of RSDNL, “is concerned with the anatomic, physiologic and neuropathologic aspects of brain and nervous system function, with a focused emphasis on the molecular and cellular mechanisms of neuronal injury and repair that are manifest in stroke and epilepsy. The proteomic and genomic responses to ischemia and particularly the phenomenon of ischemic tolerance and its neuroprotective mechanisms in the brain, are areas of concentrated interest”. Currently there are multiple NIH-funded studies in the RSDNL that address proteomic and genomic changes in the brain after ischemia. The other areas of research interest in the RSDNL include epileptic and traumatic brain injury.” “We are pleased to see more researchers using proteomics data as well as expression data in design of their experiments” said Julie Bryant, Vice President of Business Development at GeneGo. “Comparing multiple data types is essential; equally important is to depict pathways and networks for biologically meaningful data integration.”
GENEGO INC. IS AWARDED PHASE II NCI GRANT FOR NETWORK BIOMARKERS IN BREAST CANCER St. Joseph, Michigan, October 3rd, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, announced today that they have been awarded a Phase II SBIR grant from the National Cancer Institute for discovery of new biomarkers implicated in breast cancer based on network analysis. The research program includes a novel large scale gene expression and genotyping study to be run at Mayo Clinic and data analysis in MetaCore™, GeneGo’s flagship data mining platform. “We are very happy to receive this Phase II award from NCI in the current highly competitive environment as it validates our commitment to scientific research and our novel, innovative ideas in pathway analysis”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “In Phase I, we made some exciting new findings in sub-categorization of breast cancers based on network analysis of previously published microarray expression data. However, the biomarkers found in such “metaanalysis” have to be validated in a new design study in a stringent clinical environment. We are pleased to collaborate with Mayo Clinic, a world leading institution in clinical and research oncology. The microarray and genotyping assays will be conducted at Mayo labs, and the analysis will be performed with state-of-the art translational medicine and systems biology tools”.
MERCK KGAA EXPANDS AND EXTENDS THEIR LICENSE OF METACORE™ FROM GENEGO St. Joseph, Michigan, September 26th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck KGaA, Germany, (in the U.S.: EMD) has expanded their MetaCore™ license to allow all Merck KGaA employees to access MetaCore™ and the license is in perpetuity. Merck KGaA values the completeness of content coverage in MetaCore™ from signaling ligands to core metabolic changes, its intuitive interface and the system’s applicability in many therapeutic areas and biomarkers. “We see MetaCore™ as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research,” said Dr Friedrich Rippmann, Director of Bio- and Chemoinformatics. “We are very pleased to expand our relationship with Merck KGaA. Our experience with them as a customer is very positive, with excellent, constructive, feedback and open exchange of development ideas” said Julie Bryant, Vice President of Business Development at GeneGo. “Now, more groups at Merck KGaA will be able to use MetaCore™ in both early discovery and new compound safety testing.”
WASHINGTON STATE UNIVERSITY EXTENDS METACORE™ LICENSES FROM GENEGO St. Joseph, Michigan, September 19th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Washington State University Tri-cities has extended their license of MetaCore™. MetaCore™’s new release 4.0 has unique features that give researchers a multi-level analysis of experimental data with respect to functional processes, diseases and consensus pathways in just one click. “We have been loyal MetaCore™ users for quite some time now and we have been able to make significant progress in our projects supported by the Department of Energy’s Low Dose Radiation Research Program. The software helped us to interpret proteomic data from irradiated cells and to identify pathways responsible for cytokine release following radiation exposure. Understanding these pathways is important for both radiation protection standards and effective use of radiation therapy to treat cancer,” said Dr. John Miller, Associate Professor, Washington State University Tri-Cities, and Emeritus staff member at Pacific Northwest National Labs. “We like the openness of MetaCore™ that allows us to understand our data in terms of biological processes, not just lists of identified proteins.” Dr. Miller focuses on biological and environmental research including radiation induced protein release. “We are very pleased that an exemplary academic such as Professor Miller finds high value in MetaCore™ as a research tool” said Julie Bryant, Vice President of Business Development at GeneGo. “Academic scientists are a fast growing and invaluable customer base for GeneGo. We like working with academics because of the high quality of research and challenging yet constructive feedback. GeneGo is known as the innovator in functional analysis, and many of our development ideas come from academic collaborations and requests.”
NIDDK RENEWS METACORE™ LICENSE AND COLLABORATES WITH GENEGO IN DIABETES RESEARCH St. Joseph, Michigan, August 15th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), has renewed its MetaCore™ license from GeneGo to continue a research collaboration with GeneGo on functional analysis of insulin-resistant diabetes in human and animal models. Diabetes, obesity, and other metabolic disorders are priority areas in GeneGo’s effort on annotation of pathways and biological networks involved in common human disorders. “Diabetes and metabolic diseases in general are of great importance for our pharmaceutical and academic customers, and we do our best to stay on top of current science in this area” says Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “Our collaboration with NIDDK, a leading research institution in metabolic diseases, is a very important part of our development program in this field.”
GENEGO IS AWARDED PHASE II SBIR GRANT FOR SYSTEMS PROTEOMICS PLATFORM St. Joseph, Michigan, August 8th, 2006 – GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today that they have received a $750,000 Phase II SBIR grant from the Department of Defense for the development of a systems biology suite for functional analysis of proteomics data. In Phase II, GeneGo will adapt its data-mining platform, MetaCore™ for handling different types of proteomics data and implement new algorithms for reconstruction of protein-state specific biological networks and pathways. “Proteomics is a central component of OMICs technologies, as it is the active protein complexes and pathways which carry out most cellular processes,” said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “However, proteomics datasets are substantially different from simpler microarray gene expression or DNA sequence data. Each protein has to be considered as a set of condition-specific posttranslational modified isoforms and splice variants, each with its own interactions space. In most cases, “small experiment” data is not available for isoform interactions, and this information needs to be extracted from proteomics experiments directly and cross-referenced with other relevant data sources. Based on Phase I results, we will implement these specifics in a novel systems proteomics platform based on MetaCore™”. In the scope of Phase II, GeneGo will work in collaboration with Professor Austin Yang’s group from the University of Southern California, Rosetta Biosoftware, Inc. and the Michigan Proteome Consortium. “We are happy to work with GeneGo on systems proteomics”, said Dr. Austin Yang. “One of the major issues facing most proteomics laboratories now is how to establish a proper bioinformatics workflow and how to adequately validate and interpret their proteomic results. Unfortunately like most “omics” analyses, because hundreds or thousands of proteins are examined in a single experiment, it is very difficult to evaluate the biological significance or resolution of any given proteomics analysis. Two years ago, we decided to incorporate GeneGo’s MetaCore™ into our proteomics data analysis workflow. By integrating the conventional proteomic analysis with a well-annotated network or pathway analysis system such as MetaCore™, we are able to quickly and subjectively evaluate our proteomic results with high confidence. For instance, recently, we have used this combination of bioinformatic and mass spectrometic approaches to address the roles of amyloid in altering synaptic signaling pathways in Alzheimer’s disease”.
APPLIED BIOSYSTEMS AND GENEGO COLLABORATE TO ADVANCE UNDERSTANDING OF TISSUE GENE EXPRESSION GeneGo Integrates Applied Biosystems Tissue Gene Expression Database into its MetaCore™ Data Mining Platform Foster City, Calif. and St. Joseph, Mich., August 3rd, 2006 – Applied Biosystems, an Applera Corporation business, and GeneGo, Inc., a leading provider of software and databases for systems biology, today announced a collaboration designed to enhance researchers’ ability to study differential gene expression in biological pathways. As part of the agreement, GeneGo has integrated the Applied Biosystems Tissue Gene Expression Database into its MetaCore™ data mining platform. The companies said the integration of this proprietary data into MetaCore™ is expected to save researchers both time and costs that would otherwise be required to generate comparable comprehensive and high-quality curated data. The combined solution facilitates microarray experiments, such as comparing gene expression changes in normal versus diseased or treated human tissues. The Tissue Expression Database, created using the Applied Biosystems Expression Array System and Human Genome Survey Microarray, is a proprietary dataset of genome-wide gene expression values from 31 normal tissues and a Universal Human Reference RNA. This extensive dataset can serve as a baseline reference for microarray results and a source for identifying tissue-specific genes. Applying highly sensitive chemiluminescent technology, advanced bioinformatics, and a combination of public and proprietary data, the Applied Biosystems Expression Array System can detect more genes with greater specificity and sensitivity than other commercially available microarray platforms. “Organ, tissue and cell type specificity are extremely important in human and other mammalian gene expression analysis,” said Tatiana Nikolskaya, chief scientific officer and founder of GeneGo. “The Applied Biosystems Tissue Expression Database is high quality, standardized and very well annotated data. We have integrated it as a tissue expression filter in our latest product release to replace the publicly available, but less consistent, UniGene data, and look forward to collaborating on additional ways to leverage our complementary solutions.” MetaCore™ is used by major pharmaceutical companies and numerous academic institutions for target selection and validation, identification of biomarkers for disease states and toxicology analysis. By enabling the visualization and analysis of complex experimental data in an integrated manner, the solution is designed for systems biology applications. MetaCore™ is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry and is designed for analysis of gene expression, genetic variations, and proteomic and metabolite profiles. Such integrated analysis helps accelerate the drug discovery and development process and also helps eliminate drug candidates that will have harmful side effects or interactions before they are tested in humans. “GeneGo has a strong track record of integrating best-of-class technologies and data into its software platform to support emerging systems biology applications,” said Carl Hull, vice president for the sequence detection system and microarray business units of Applied Biosystems. “This collaboration represents a mutually beneficial way to support our respective customers in their endeavors to turn their valuable data into meaningful information in the drug discovery and development process.” About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers. Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera Genomics is also discovering and validating therapeutic targets, and it is seeking to develop therapeutic products based on these discovered targets through strategic partnerships. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.
GALAPAGOS LICENSES METACORE™ FROM GENEGO St. Joseph, Michigan, August 1st, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Galapagos NV, a genomics-based drug discovery company, will be using the integrated software suite MetaCore™ for its internal research across several disease areas including osteoporosis, osteoarthritis and rheumatoid arthritis. "We were satisfied with the demonstrated capabilities and quality of data obtained through MetaCore™,” commented Dr. Graham Dixon, Senior Vice President of Drug Discovery at Galapagos. “We have already identified and validated novel, proprietary targets using our adenoviral technology platform in bone and joint diseases; applying MetaCore™ to this target set could allow us to gain valuable insights at the system level thereby improving our understanding of the underlying disease biology and increasing our speed and success in finding new drugs against these targets." “We are very pleased to welcome Galapagos as a new customer,” said Julie Bryant, Vice President of Business Development at GeneGo. “Over the last year, systems analysis of biological data has become mainstream, rather than a niche application, for high volume high throughput genomics labs. The new customization tools and expansion of knowledge content in disease areas make MetaCore™ applicable for focused research programs at specialized drug discovery companies. We are proud that Galapagos has selected MetaCore™ in the competitive market of pathways tools.”
GENEGO AND ELSEVIER MDL COLLABORATE TO PROVIDE SEAMLESS ACCESS TO COMPOUND DATABASES, PATENTS, LITERATURE AND PATHWAYS St. Joseph, Michigan, July 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis and Elsevier MDL, a leading provider of scientific content, informatics framework and workflow applications for pharmaceutical research, announced the collaboration. The latest version of GeneGo’s data mining platform MetaCore™ 4.0 will be seamlessly integrated with the MDL® suite of databases via the DiscoveryGate® content platform. Researchers will be able to identify drug targets and bioactive compounds via pathway analysis and retrieve comprehensive information on their synthesis, biological effects, commercial availability and relevant literature within one application. "The integration of MDL® databases with GeneGo's pathways information systems enables scientists to bridge the gap between cell biology and organic chemistry," comments Steve Young, Director of MDL Content Strategy. "For the first time, biologists will be able to quickly review cheminformatics data of small molecules involved in biological pathways and chemists will be able to view molecular pathway information related to their lead compounds." “Lately, a number of customers approached us with requests for functional analysis of the effects of drug-like compounds rather than genomic data,” says Julie Bryant, VP Business development at GeneGo. “Although pathways and network analysis of bioactive compounds is a common practice in MetaCore™, we partnered with Elsevier MDL for in depth coverage of literature and patentderived information relevant for compounds. We are very pleased to be working with Elsevier MDL, the market leader in medicinal chemistry knowledge databases, Integration with the Elsevier MDL chemistry space opens up new applications for our products in medicinal chemistry, including high-throughput and high-content screening, hit selection and validation, lead development programs and chemogenomics.” About Elsevier MDL Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information visit www.elsevier.com.
REPRODUCTIVE MEDICINE ASSOCIATES OF NEW JERSEY ENTERS MULTI YEAR AGREEMENT WITH GENEGO TO ACCESS METACORE™ St. Joseph, Michigan, July 13th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Reproductive Medicine Associates (RMA) of New Jersey have licensed MetaCore™ to use for research and in their clinic. Primarily, MetaCore™ will be used for analysis of gene expression data from individual human oocytes and blastomers. It was important for RMA that MetaCore™ has comprehensive curated content in the area of reproduction and is capable of concurrent analysis of multiple patients’ datasets. ”We are pleased to have acquired this excellent research tool from GeneGO. MetaCore™ will increase our ability to translate research discoveries into clinical applications that will improve the quality of life for patients with infertility," said Dr. Nathan Treff, Principle Investigator of Molecular Biology at RMA of New Jersey. “We are very pleased to see our tools licensed by RMA”, said Julie Bryant, Vice President of Business Development at GeneGo. “MetaCore™ has been applied extensively in the area of reproductive medicine by several pharmaceutical companies and academic groups, but this is the first time it will be used by health care practitioners. This is very encouraging as our ultimate goal is to adapt systems data analysis technology to the needs of doctors and individual patients.”
SIENA BIOTECH EXPANDS METACORE™ LICENSE FROM GENEGO St. Joseph, Michigan, July 5th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Siena Biotech has expanded the number of MetaCore™ licenses obtained from GeneGo. MetaCore™’s technology platform’s capacity to integrate multiple data types including proteomics and chemogenomics data was valued by Siena Biotech together with the quality of content in neurological diseases. “We appreciate MetaCore™’s flexibility and GeneGo’s ability to quickly implement customer feedback,” said Dr. Georg C. Terstappen, Vice President Discovery Research, of the Italian Company. “GeneGo and Siena Biotech in their respective fields are leading the way in pathway proteomics: we expect advantages for both companies form this collaboration.” “We are very pleased to expand our relationship with Siena Biotech” said Julie Bryant, Vice President of Business Development at GeneGo. “We are seeing more of our customers expanding the scope of data types analyzed in MetaCore™ in their R&D efforts. MetaCore™ is well equipped for this with its capacity to concurrently visualize, score and process gene expression, proteomic, metabolomic and compound data.”
NHLBI EXPANDS THEIR METACORE™ LICENSE TO COVER NHLBI, CORE, CIT AND CRITICAL CARE MEDICINE DEPARTMENT St. Joseph, Michigan, June 27th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that their multi year agreement with NHLBI will be extended and expanded to cover National Heart, Lung and Blood Institute core microarray group, the Center for Information Technology and the Critical Care Medicine Department of the NIH Clinical Center. MetaCore™ will also be used throughout their new systems biology group and it will be an integral part of their development. The NHLBI Microarray Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. The large amount of data generated from such experimentation requires complex analytical tools for efficient data capture, analysis and interpretation of results. As a central part of its role, the core provides computational and research tools to investigators in NHLBI, CIT and CCMD and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. GeneGo’s MetaCore™ data mining software will provide factual, statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes, and DNA sequence variations. There are currently more than fifty projects in the core using Affymetrix technology that will be directly improved by access to this software. It is hoped that the application of the MetaCore™ analysis program would help decipher the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicines. “We have enjoyed working with NHLBI over the years and we look forward to further expand these relationships with a larger group at the center,” said Julie Bryant, Vice President of Business Development at GeneGo. “The field of functional data mining is evolving very rapidly, and collaborations with the leading academic institutions help us to be on top of state of art technology. MetaCore™ is a very dynamic platform, and the feedback from collaborators is essential in its development.”
BOEHRINGER INGELHEIM LICENSES METACORE™ FROM GENEGO FOR TOXICOGENOMICS STUDIES St. Joseph, Michigan, June 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Boehringer Ingelheim has licensed its data mining suite, MetaCore™, primarily for toxicogenomics research. MetaCore™ is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry. “Toxicogenomics is one of the main applications of MetaCore™, and we pay a lot of attention to the field in product development.” said Julie Bryant, Vice President of Business Development at GeneGo. “We manually curate all major toxicity journals and develop tools and workflows specifically for the analysis of toxicogenomics datasets; the work is partly sponsored by an NIEHS grant. MetaCore™ was featured in many posters and presentations at the recent Society of Toxicology meeting in San Diego, and is applied by a growing number of toxicogenomics groups in industry and academia.” About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 45 countries and about 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending approx one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com
GENEGO'S METACORE™ DATA MINING PLATFORM NOW FULLY-COMPATIBLE WITH AGILENT'S GENESPRING GX BIOINFORMATICS SOLUTION St. Joseph, Michigan, June 6th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the ability to integrate GeneGo’s MetaCore™ and Agilent Technologies Inc.’s GeneSpring software applications. Users of both will enjoy the interoperability between the two systems as well as the seamless workflow for statistical and functional analysis of gene expression data. Agilent’s GeneSpring is a widely used bioinformatics solution for microarray analysis and data management. MetaCore™ is the leading functional data mining platform designed for the analysis of different types of experimental data in the context of pathways, networks, cellular processes, diseases and toxic categories. “With this relationship, we respond to multiple customer requests for integration with GeneSpring,” said Julie Bryant, vice president of Business Development at GeneGo. “GeneGo has an open, market-driven partnering philosophy, and we are happy that Agilent has a similar viewpoint. We look forward to receiving more customer feedback and further developing our systems’ interoperability.” “The use of informatics to enable life science research has changed dramatically in the last 18 months,” said Jordan Stockton, Agilent Informatics marketing manager. “Today, researchers demand applications that allow them to pool evidence from as many sources as possible. The integration of GeneSpring and MetaCore allows leading scientists to rapidly synthesize information about pathways and molecular interactions with those from microarray technologies.”
PEAKADILLY LICENSES METACORE™ FROM GENEGO St. Joseph, Michigan, May 15th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Peakadilly NV, Belgium, has licensed MetaCore™ for use in proteomics research. MetaCore™ will be available via the intranet to Peakadilly. It was important to Peakadilly that MetaCore™ content covers multiple levels of protein interactions from extra cellular stimuli through signaling to core metabolism and that MetaCore™ is well designed for proteomics research. "We were impressed by the quality of the content and unique capabilities of the visualization and analysis software in MetaCore™," said Dr Koen Kas, CSO of Peakadilly. "We are very happy that Peakadilly, well known for its innovative and high performance proteomics technologies, has chosen MetaCore™ as a functional analysis engine. We will be working closely with them as we further develop our proteomics offering," said Julie Bryant, Vice President of Business Development at GeneGo. "Compared to genomics, proteomics data is more complex, yet they provide unique insights about active cell machinery. Proteomics data mining is an important area in our technology development and one for which we have been awarded government grants." About Peakadilly Peakadilly was founded in late 2004 to exploit the protein biomarker discovery technology developed at VIB and the University of Ghent. In this short time, it has successfully implemented the technology and won revenue generating projects with big pharma. It applies the technology both to third party projects and to its own projects for developing a new generation of diagnostics and pharmacodiagnostic products.
GENEGO AND XB TRANSMED SOLUTIONS PROVIDE INTEGRATED SOLUTIONS TO THE TRANSLATIONAL MEDICINE MARKET St. Joseph, Michigan, April 24th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology and XB TransMed Solutions, a translation medicine software and services company, today announced that their flagship products, MetaCore™ and XB-BioIntegration Suite (XB-BIS) are fully integrated. Mutual customers can capture, manage and mine integrated clinical, preclinical and molecular data in its various forms and statistically analyze data associations using XB-BIS, and functionally analyze the associated results in the context of biological pathways, networks, cellular processes and disease networks in MetaCore™. "XB-BIS has been developed to fulfill the need in translational medicine for efficient data capture, management, analysis and reporting in an intuitive workflow that resembles the natural translational path from early hypothesis generation to validation and application in the areas of clinical diagnostics and intervention" said Dr. Craig Webb, Program Director for Translational Medicine at the Van Andel Institute. "Integration with the MetaCore™ systems biology toolsets permits the user to seamlessly integrate back and forth between expanding knowledge and enhanced application." "Over the past year, we have seen an increasing demand in systems biology solutions from the clinical trial market," said Julie Bryant, Vice President of Business Development at GeneGo. "Understanding the differences of drug effects on individual patients is a very challenging task, which requires state of the art tools in both translational medicine and functional data mining. We are very pleased to join forces with XenoBase inventors Dr Craig Webb and Dr. Jeremy Miller at the Van Andel Institute to develop analytical workflows for the clinical environment." About XB TransMed Solutions XB TransMed Solutions, was founded as a next generation life science application and services company with headquarters in Grand Rapids, Michigan. The focus of XB TransMed Solutions is to provide leading edge software and service solutions expediting the complete life science work process from novel discovery to clinical application in an integrated environment. XB Trans Med markets its Bio-Integration Suite as a fully integrated biological and medical informatics solution that allows users to generate, refine, and validate causal hypotheses across disparate data sets. The purpose is to provide a complete solution in the area of translational biomedical research, whereby bench-side research can rapidly lead to discoveries that can be readily applied to bedside medicine. XB Bio-Integration Suite are trademarks of XB TransMed Solutions, LLC
INFORSENSE® AND GENEGO JOIN FORCES TO DELIVER INTEGRATED PATHWAY-BASED WORKFLOWS TO ENABLE SYSTEMS BIOLOGY RESEARCH
London, UK and Cambridge, MA, USA, April 11th, 2006 - InforSense Ltd., the leader in integrative analytics platforms, today announced that the company has joined forces with GeneGo, a leading provider of systems biology tools and databases. The companies are integrating their technologies to allow researchers to better probe their data and share their work process across different research domains. GeneGo has also joined the InforSense Open Workflow Partner Network. The integration of GeneGo's unique reference system for curated pathway analysis and InforSense's integrated, interactive workflow-based data mining technology allows researchers to query their data and share their results across the research and development value chain. In addition to the integration of InforSense KDE and MetaCore™, which is already available, the companies are in the process of integrating InforSense KDE with both MetaDrug™ and MetaBase™. Customer feedback supports integration of GeneGo's software suite with the proven InforSense workflow technology, as researchers will be enabled to bridge domains such as genomics and metabolomics with high confidence data using a systems biology approach. In addition, users will be able to annotate pathway data with experimental results and clinical data and thereby better predict patient outcomes. "The collaboration between InforSense and GeneGo will deliver to thousands of users the needed environment for leveraging high-throughput biology and chemistry data more effectively for better and faster decision-making within the life science industry," said Julie Bryant, Vice President of Business Development of GeneGo. "InforSense workflows enable life science researchers to compose and execute scientific analyses quickly and easily without programming, sharing both methods and results with co-workers." "MetaCore has grown to become a key component in the research toolbox in the life sciences, particularly within the pharmaceutical industry, and we are pleased to have the opportunity to work with GeneGo," commented Dr. Jonathan Sheldon, Chief Scientific Officer, InforSense. "The integration of pathway analysis with InforSense KDE is a key component of our multidisciplinary analytics platform for Systems Biology." About InforSense InforSense Ltd., the leader in integrative analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, financial services companies, and research institutes are using the company's flagship product, InforSense KDE, to enhance productivity across life science R&D, healthcare, and business analytics. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts. About InforSense KDE Using InforSense KDE, enterprises rapidly integrate and deliver virtually any data source, analytic software tool, service or application within a single informatics framework. Users link these components via visual workflows to dynamically answer any question using their data, however complex or transient. Organizations can also mine their analytical processes to discover and deploy expertise and best practices. InforSense KDE provides an open, extensible service-oriented architecture, built using industry standards including J2EE, XML, and WSDL. InforSense IOE is a state-of-the-art solution for enterprise-wide integrative analytics using Oracle's advanced information management and processing capabilities. About InforSense Partner Network The InforSense Partner Network provides interoperability between industry leading technologies via InforSense KDE. Mutual customers benefit from proven integration between their tools of choice across scientific and business analytics via an intuitive visual workflow interface. For more information visit www.inforsense.com InforSense, TextSense and the InforSense logo are registered trademarks of InforSense Limited. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.
BERLEX SIGNS LICENSE AGREEMENT WITH GENEGO St. Joseph, Michigan, March 13th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that it has entered into a licensing agreement with Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), for MetaCore™. The license provides researchers at Berlex and its German parent company with use of the MetaCore™ platform for analysis of gene expression, proteomic, metabolic and other high-throughput data in multiple therapeutic areas, including oncology, and in diagnostic applications. "We are very pleased to bring MetaCore™ into our research," said Hugh Salamon, senior computational biologist, Berlex. "It is essential to exploit curation of scientific findings given the large body of knowledge relevant to therapeutic research. GeneGo is providing us with an important view of current knowledge of mammalian signaling, metabolism, drugs and diseases through the MetaCore™ platform." "We are very pleased that researchers at Berlex Biosciences, the US research center for Berlex, will be using MetaCore™ and to have the company as a GeneGo customer," said Julie Bryant, Vice President of Business Development at GeneGo. "Berlex researchers will be among more than 140 unique accounts and thousands of users. Feedback from such partnerships help us enhance MetaCore™ as a versatile, multi-purpose data mining tool applicable in diverse life science projects.
GENEGO EXPANDS LICENSE WITH JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT TO INCLUDE METABASE™ ACCESS St. Joseph, Michigan, February 20th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Johnson & Johnson Pharmaceutical Research & Development, (J&JPRD), a division of Janssen Pharmaceutica N.V., has extended their MetaCore™ license to now include MetaBase™, a database J&JPRD will primarily use for biomarker discovery. "We are pleased to have this relationship extended," said Julie Bryant, Vice President of Business Development at GeneGo. "We look forward to enhancing our collaboration with the MetaBase™ integration."
GENEGO AND GENEDATA COMBINE FORCES TO PRODUCE ULTIMATE ENTERPRISE PLATFORM St. Joseph, Michigan, February 13th, 2006 - GeneGo Inc. and Genedata AG, providers of computational solutions for systems biology and biomarker discovery, announce that their computational systems have successfully been integrated to support a seamless data analysis workflow. The workflow supports target selection and validation as well as diagnostic and biomarker applications. "Today, drug discovery scientists handle very complex "genome wide" experimental datasets. To cope with such complexity they need a variety of analytical approaches and databases not available from any single source. Therefore, cooperation between computational biology specialists is logical and beneficial for end users", explained Julie Bryant, Vice President of Business Development at GeneGo Inc. GeneGo's flagship analytical suite, MetaCore™ combines a manually curated database of clinical and pre-clinical biology information and bioactive compounds with comprehensive pathways and network analyses. Bryant added, "MetaCore™ can now be connected with Genedata Expressionist® and Genedata Phylosopher®, so mutual customers will be able to move iteratively between the software systems seamlessly and inter-operatively". "Genedata's open and scalable architecture provides a strong basis for integration with client and third party content", says Dr. Daniel Keesman, CEO of Genedata AG. Expressionist enables omics data and associated information to be imported, processed and analyzed in an automated and repeatable workflow. Phylosopher has been integrated closely with MetaCore's visualization tools to identify and prioritize pathways affected by disease. The integrated solution achieves unrivaled standards in research information management and decision support. Dr. Keesman added, "This integration has been customer-led and helps scientists place their results in biological context, thus deriving maximum benefit from experimental data".
SCITEGIC'S ISV PARTNER PROGRAM WELCOMES TWENTIETH MEMBER SAN DIEGO, CA, January 9, 2006 - SciTegic, the leader in data pipelining and workflow tools announced today that four new members have joined its Independent Software Vendor (ISV) partner program. The program's aim is to compile a collection of high value life sciences applications to address customer needs for increased software interoperability. Through new collaborations with ACD/Labs, Bio-Rad, GeneGo, and Partek, scientists in drug discovery will obtain access to new, integrated software products that will help them solve more complex research problems in a more efficient manner. "We are pleased to see a rapidly growing community adopt the Pipeline Pilot platform for life sciences software deployment", says Mathew Hahn, Vice President and General Manager of SciTegic. "By promoting partnerships with key scientific software vendors, we allow our customers to leverage existing, specialized software solutions in order to increase their R&D productivity." "Our joint customers will be able to access ACD/Labs' PhysChem and Nomenclature batch software (www.acdlabs.com) from within SciTegic's Pipeline Pilot framework, leading to more efficient and repeatable discovery processes," says Antony Williams, Vice President and Chief Science Officer of ACD/Labs. "The combination of our KnowItAll® technologies (www.knowitall.com/adme) for in silico ADME/Tox with SciTegic will allow drug discovery researchers to more accurately predict key properties for potential drug candidates, thus accelerating the drug discovery process," says Gregory M. Banik, Ph.D., General Manager of Bio-Rad Laboratories, Informatics. "We are excited to deliver our technology as part of SciTegic's Pipeline Pilot platform," says Julie Bryant, Vice President of Business Development of GeneGo. "Joint customers will be able to increase their research efficiency by rapidly incorporating pathway information in their workflows." "We are pleased to join SciTegic's ISV program," said Tom Downey, President and CEO of Partek, "as it allows us to bring together the data workflow capabilities of Pipeline Pilot with the statistics and interactive visualization capabilities that our software offers, allowing life sciences researchers to make better decisions."
MERCK EXTENDS GLOBAL ENTERPRISE LICENSE OF METACORE™ AND METADRUG™ FOR TWO ADDITIONAL YEARS St. Joseph, Michigan, January 9th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck & Co., Inc. has extended its global enterprise agreement for two additional years. Merck researchers around the world will continue to use the MetaCore™ data mining suite in research and development activities. The researchers will also retain direct access to MetaBase™, a comprehensive database of mammalian protein interactions, signaling and metabolic pathways, bioactive compounds, and diseases manually curated by GeneGo from full text experimental literature. MetaCore™ and MetaBase™ have been integrated with Merck's discovery informatics platform and are leveraged across multiple therapeutic areas. "Merck has been a great partner, and we have enjoyed interacting with their scientists. As a result of this collaboration, we have developed a number of new data analysis and visualization features now available in MetaCore™. We will continue to encourage this high level of communication as we move forward in 2006," said Julie Bryant, VP business development. "The field of functional data analysis is maturing rapidly, and it is crucial for us to work closely with state-of-art research teams, such as those at Merck."
|
